Drug Approval | November 01, 2023
Lupin Mandideep plant gets USFDA green signal
The inspection of the facility conducted from August 7 to August 11, 2023
The inspection of the facility conducted from August 7 to August 11, 2023
India is following a holistic and inclusive approach in alignment with the vison of Universal Health Coverage and the resolute commitment to ‘leave no one behind
The drug will be marketed by Sun Pharma under the brand name RYTSTAT
The initiative will focus on advocating for cleaner air
2023 Nobel laureates discovered how pseudouridine could make mRNA suitable for vaccines
Dr Reddy’s Laboratories recorded revenue of Rs 6,880.20 crore during the quarter
The companies plan to start a pivotal Phase 3 trial in the coming months
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
With the establishment of five different precious metals alloy powder production methods
In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)
Subscribe To Our Newsletter & Stay Updated
